ReviewPharmaceuticals (Basel, Switzerland)2025

Discovery of Personalized Treatment for Immuno-Metabolic Depression-Focus on 11beta Hydroxysteroid Dehydrogenase Type 2 (11betaHSD2) and Toll-like Receptor 4 (TLR4) Inhibition with Enoxolone.

Harald MurckPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.